Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 123

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 123
---
 Debt SPA with an accredited investor, pursuant to which in exchange for the satisfaction of our debt in the aggregate amount of $4.0 million held by the investor, we agreed to issue 806,452 newly designated convertible preferred shares, at a purchase price of $4.96 (rounded). The preferred shares contain a conversion price of $4.96 per share. The transactions contemplated by the October Debt SPA closed on October 10, 2024.

On September 16, 2024, we and a certain institutional investor entered into a warrant amendment agreement to amend those warrants issued by us to the investor, collectively, to purchase up to 172,837 Common Shares. The amendment makes certain adjustment to the definition of a “Fundamental Transaction” in such common warrants. In addition, we agreed to adjust the exercise price in such to CHF 0.80 (on a post-split basis), and agreed to issue to the investor pre-funded warrants to purchase up to 191,431 Common Shares.

On June 28, 2024, we entered into a securities purchase agreement for the issuance of 81,944 Common Shares at a purchase price of $9.60 per share. The offering closed on July 1, 2024. Investors also received unregistered warrants to purchase up to 81,944 Common Shares at an exercise price of $9.60 per share. These warrants are exercisable upon issuance and will expire five years from the date of issuance. The offering resulted in gross proceeds of $786,660. The net proceeds will be used for working capital and general corporate purposes.

H.C. Wainwright & Co., LLC served as the exclusive placement agent for the offering. We agreed to pay the placement agent a cash fee of 7.0% of the gross proceeds, a management fee of 1.0% of the gross proceeds, and $50,000 for accountable expenses. Additionally, we issued to the placement agent warrants to purchase up to 5,736 Common Shares at an exercise price of $12.00 per share. These warrants are exercisable from the date of issuance until five years from the commencement of sales in the offering.

On March 20, 2024, we entered into a securities purchase agreement providing for the issuance in a registered direct offering of 175,000 Common Shares at a purchase price of $10.00 per share that closed on March 22, 2024. In addition, the investors received unregistered warrants to purchase up to an aggregate